news
NICE recommends therapy duo for advanced leukaemia
Janssen states Imbruvica® plus venetoclax will provide "a much-needed new treatment option" for chronic lymphocytic leukaemia.
List view / Grid view
Imbruvica (ibrutinib)
news
Pharmacovigilance Risk Assessment Committee (PRAC) meeting highlights, Oct 2021
EMA's drug safety committee (PRAC) assessed risks with COVID-19 vaccines and identified no risk of death with Imbruvica and ACE inhibitors.
news
Pharmacovigilance Risk Assessment Committee (PRAC) meeting highlights, September 2021
The EMA’s drug safety committee (PRAC) reviewed COVID-19 vaccine risks and issued a new safety signal for Imbruvica with rituximab.
news
AstraZeneca reveals $15.54 billion in revenues in H1 2021
H1 financial results show AstraZeneca’s revenues grew by 23 percent in 2021, with $14.37 billion attributed to activities aside from COVID-19 vaccine sales.
news
Chemotherapy-free combination shows potential in lymphocytic leukaemia trial
Imbruvica® (ibrutinib) plus Venclexta®/Venclyxto® (venetoclax) resulted in 95 percent of chronic lymphocytic leukaemia patients surviving without disease progression for two years.
news
Imbruvica®-based regimens induce lasting remissions in leukaemia trials
Imbruvica® (ibrutinib) plus ventoclax and single-agent Imbruvica induced remissions lasting up to seven years in first-line treatment of chronic lymphocytic leukaemia.
news
FDA approves IMBRUVICA® (ibrutinib) for treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma
IMBRUVICA (ibrutinib), in combination with rituximab, has been given approval in the US for the treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma.
article
Top 10 drugs by annual revenue in 2025
Researchers have revealed the top 10 drugs by annual revenue in 2025. Here, we investigate the indications that necessitate these treatments and the delivery systems they employ.
news
Imbruvica® granted expanded use from European Commission
The European Commission has approved the drug for two indications: chronic lymphocytic leukaemia and Waldenström's macroglobulinemia.
news
Price drop means leukaemia CDF drug will be routinely available
2 December 2016 | By Niamh Louise Marriott, Digital Editor
Ibrutinib had only previously been available through the CDF. Following a reduction in its price for the NHS, it is now recommended in further guidance...
news
NICE does not recommend Janssen’s Waldenstrom’s macroglobulinaemia candidate
17 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The National Institute of Health and Care Excellence (NICE) has published draft guidance that does not recommend Janssen’s Imbruvica (ibrutinib) for treating some people with Waldenstrom’s macroglobulinaemia – a rare type of slow growing non-Hodgkin’s lymphoma.
news
NICE says Novartis’ and Janssen’s cancer drugs are not cost effective
18 August 2016 | By The National Institute for Health and Care Excellence (NICE)
In new draft guidance, the National Institute for Health and Care Excellence (NICE) has advised that everolimus, for treating advanced breast cancer after endocrine therapy, and ibrutinib, for treating relapsed or refractory mantle cell lymphoma, two drugs on the Cancer Drugs Fund are not cost effective.
news
FDA grants Breakthrough designation to ibrutinib in cGVHD
1 July 2016 | By Victoria White, Digital Content Producer
The US Food and Drug Administration (FDA) has granted a fourth Breakthrough Therapy Designation for ibrutinib (Imbruvica) as monotherapy for the treatment of patients with chronic graft-versus-host-disease (cGVHD) after failure of one or more lines of systemic therapy.
news
NICE asks Janssen to put ibrutinib forward for the CDF
1 June 2016 | By Victoria White, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) has asked Janssen to set out a case for including its chronic lymphocytic leukaemia (CLL) drug ibrutinib (Imbruvica) in the Cancer Drugs Fund (CDF).
news
EC approves ibrutinib for patients with newly diagnosed CLL
31 May 2016 | By Victoria White, Digital Content Producer
The European Commission (EC) has approved Imbruvica (ibrutinib) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
